BioSpace News Archive

Seattle Genetics, Inc. and Astellas Pharma Inc. announced that a phase 3 trial of PADCEV® met its primary endpoint of overall survival compared to chemotherapy.

5-Year Data from Phase 3 SOLO-1 Trial Represents Longest Follow-Up Analysis for Any PARP Inhibitor in First-Line Maintenance Setting Following Response to Platinum-Based Chemotherapy

The ongoing COVID-19 pandemic is projected to generate prominent sales avenues in the global vaccine glass bottle market during the tenure of 2019 to 2029.

The demand within the global hormonal contraceptives market is rising at a stellar pace in recent times.

High performance liquid chromatography is one of the techniques used to separate, quantitate, and identify components in the given mixture.

Inventive technologies and cutting-edge research have led to the development of several innovative magnetic resonance imaging equipment, helping patients live healthier and longer lives.

Increasing the dose frequency of lanreotidefrom monthly to bi-monthly achieved a progression-free survival of 8.3 months in patients with progressive midgut neuroendocrine tumors (NETs) and 5.6 months in patients with progressive pancreatic NETs

Autolus Therapeutics plc announced new data highlighting progress on AUTO3, the company’s CAR T cell therapy being investigated in the ALEXANDER study, a Phase 1/2 clinical trial in relapsed/refractory diffuse large B cell lymphoma, during the European Society for Medical Oncology Virtual Congress 2020, beginning 18 September.

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. announced the publication of detailed results from the Phase III JAVELIN Bladder 100 study online ahead of print in The New England Journal of Medicine.

Beechtree Labs has chosen Curavit Clinical Research for a fully decentralized clinical trial to investigate a promising Covid-19 therapy.